Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 8:12:e44825.
doi: 10.2196/44825.

Fertility Preservation Techniques in Neuro-Oncology Patients: Protocol for a Systematic Review

Maia Osborne-Grinter #  1 , Offorbuike Chiamaka Bianca  2 , Jasleen Sanghera  3 , Chandrasekaran Kaliaperumal  4
Affiliations

Fertility Preservation Techniques in Neuro-Oncology Patients: Protocol for a Systematic Review

Maia Osborne-Grinter et al. JMIR Res Protoc. .

Abstract

Background: Advancements in cancer treatments have successfully improved central nervous system (CNS) cancer survivorship and overall quality of life. As a result, the awareness of the importance of fertility preservation techniques is increasing. Currently, a range of established techniques, such as oocyte cryopreservation and sperm cryopreservation, are available. However, oncologists may be hesitant to refer patients to a reproductive specialist.

Objective: The primary aim of the proposed systematic review is to assess the best evidence for fertility preservation techniques used in patients with CNS cancers. It also aims to evaluate outcomes related to their success and complications.

Methods: This protocol was produced in adherence with the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols). Electronic databases will be systematically searched to identify studies that meet our eligibility criteria. Studies will be included if they report at least one type of fertility preserving or sparing technique in male patients of any age and female patients aged <35 years. Animal studies, non-English studies, editorials, and guidelines will be excluded from the review. From the included studies, data will be extracted and synthesized by using a narrative approach and summarized in tables. The primary outcome will be the number of patients successfully undergoing a fertility preservation technique. The secondary outcomes will include the number of retrieved oocytes, the number of oocytes or embryos vitrified for cryopreservation, clinical pregnancy, and live birth. The quality of the included studies will be assessed by using the National Heart, Lung, and Blood Institute risk-of-bias tool for any type of study.

Results: The systematic review is expected to be completed by the end of 2023, and results will be published in a peer-reviewed journal and on PROSPERO.

Conclusions: The proposed systematic review will summarize the fertility preservation techniques available for patients with CNS cancers. Given the improvement in cancer survivorship, it is becoming increasingly important to educate patients about fertility preservation techniques. There are likely to be several limitations to this systematic review. Current literature is likely to be of low quality due to insufficient numbers, and there may be difficulty in accessing data sets. However, it is our hope that the results from the systematic review provide an evidence base to help inform the referral of patients with CNS cancers for fertility preservation treatments.

Trial registration: PROSPERO CRD42022352810; https://tinyurl.com/69xd9add.

International registered report identifier (irrid): PRR1-10.2196/44825.

Keywords: CNS cancer; artificial insemination; assisted reproductive technology; awareness; cancer; central nervous system; electronic database; fertility; fertility preservation; fertility tourism; gestational surrogacy; gynecologist; gynecology; human reproduction; in vitro fertilization; infertility; intracytoplasmic sperm injection; neuro-oncology; oncology; patient; reproduction; reproductive; surrogate; test tube baby; tool; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7–30. doi: 10.3322/caac.21442. https://onlinelibrary.wiley.com/doi/10.3322/caac.21442 - DOI - DOI - PubMed
    1. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, Donaldson SS, Byrne J, Robison LL. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009 Jun 01;27(16):2677–2685. doi: 10.1200/JCO.2008.20.1541. https://europepmc.org/abstract/MED/19364965 JCO.2008.20.1541 - DOI - PMC - PubMed
    1. Anderson RA, Wallace WHB. Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril. 2013 May;99(6):1469–1475. doi: 10.1016/j.fertnstert.2013.03.014. https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(13)00415-9 S0015-0282(13)00415-9 - DOI - PubMed
    1. Meirow D, Biederman H, Anderson RA, Wallace WHB. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010 Dec;53(4):727–739. doi: 10.1097/GRF.0b013e3181f96b54.00003081-201012000-00004 - DOI - PubMed
    1. National Institute for Health and Care Excellence Fertility problems: assessment and treatment. National Institute for Health and Care Excellence. 2013. [2023-04-24]. https://www.nice.org.uk/guidance/CG156 .